Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 7, 2022
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
Matthew Harrison Maintained (AKRO) at Hold with Increased Target to $40 on, Nov 7th, 2022
Matthew Harrison of Morgan Stanley, Maintained "Akero Therapeutics, Inc." (AKRO) at Hold with Increased Target from $30 to $40 on, Nov 7th, 2022.
Matthew has made no other calls on AKRO in the last 4 months.
There is 1 other peer that has a rating on AKRO. Out of the 1 peers that are also analyzing AKRO, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Liisa Bayko of "Evercore ISI Group" Upgraded from Hold to Buy and Increased Target to $50 on, Wednesday, September 14th, 2022
